Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
نویسندگان: فاطمه رنجبر , همایون صادقی بازرگانی , اصغر ارفعی , مصطفی فرح بخش
کلمات کلیدی: hyperprolactinemia, aripiprazole, risperidone, psychotic disorder
نشریه: 41882 , 11 , 2015 , 2015
| نویسنده ثبت کننده مقاله |
فاطمه رنجبر |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
روانپزشکی و علوم رفتاری |
| کد مقاله |
72592 |
| عنوان فارسی مقاله |
Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia |
| عنوان لاتین مقاله |
Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia |
| ناشر |
6 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
خیر |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Background: Antipsychotics have been used for more than 50 years in the treatment of
schizophrenia and many other psychiatric disorders. Prolactin levels usually increase in patients
treated with risperidone. Aripiprazole, which has a unique effect as an antipsychotic, is a D2
receptor partial agonist. It is an atypical antipsychotic with limited extrapyramidal symptoms.
Since it acts as an antagonist in hyperdopaminergic conditions and as an agonist in hypodopamin-
ergic conditions, it does not have adverse effects on serum prolactin levels. The present study
aimed to investigate the effect of aripiprazole on risperidone-induced hyperprolactinemia.
Methods: This before-and-after clinical trial was performed in 30 patients. Baseline prolactin
levels were measured in all patients who were candidates for treatment with risperidone. In
subjects with elevated serum prolactin, aripiprazole was added to their treatment. Serum prolactin
levels were measured during the first week, second week, and monthly thereafter for at least
3 months or until prolactin levels became normal. The data were analyzed using Stata version
11 software. Survival analysis and McNemar’s test were also performed.
Results: The mean age of the participants was 30.8 years. Prolactin levels normalized in
23 (77%) participants during the study, and menstrual disturbances normalized in 25 (83.3%).
Prolactin levels normalized in most patients between days 50 and 110. The median time to
recovery based on normalization of prolactin was 84 days. Psychotic symptoms were present
in 26 subjects at baseline, but in only two by the end of the study.
Conclusion: The results of this study confirm the effects of aripiprazole in reducing risperidoneinduced
hyperprolactinemia
and
its
sequelae.
Aripiprazole
also
led
to
significant
improvements
in
psychotic
symptoms when compared with those present prior to treatment with aripiprazole. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| 1.pdf | 1399/03/27 | 742951 | دانلود |